AR108790A1 - Métodos y composiciones para el tratamiento de la enfermedad celíaca, de la sensibilidad al gluten no celíaca y de la enfermedad celíaca refractaria - Google Patents

Métodos y composiciones para el tratamiento de la enfermedad celíaca, de la sensibilidad al gluten no celíaca y de la enfermedad celíaca refractaria

Info

Publication number
AR108790A1
AR108790A1 ARP170101652A ARP170101652A AR108790A1 AR 108790 A1 AR108790 A1 AR 108790A1 AR P170101652 A ARP170101652 A AR P170101652A AR P170101652 A ARP170101652 A AR P170101652A AR 108790 A1 AR108790 A1 AR 108790A1
Authority
AR
Argentina
Prior art keywords
celiac
celiac disease
antibody
sequence
compositions
Prior art date
Application number
ARP170101652A
Other languages
English (en)
Spanish (es)
Inventor
Wayne H Tsuji
Francisco Leon
Original Assignee
Amgen Inc
Celimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Celimmune Llc filed Critical Amgen Inc
Publication of AR108790A1 publication Critical patent/AR108790A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
ARP170101652A 2016-06-15 2017-06-15 Métodos y composiciones para el tratamiento de la enfermedad celíaca, de la sensibilidad al gluten no celíaca y de la enfermedad celíaca refractaria AR108790A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2016/037708 WO2017217985A1 (en) 2016-06-15 2016-06-15 Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease

Publications (1)

Publication Number Publication Date
AR108790A1 true AR108790A1 (es) 2018-09-26

Family

ID=56292925

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101652A AR108790A1 (es) 2016-06-15 2017-06-15 Métodos y composiciones para el tratamiento de la enfermedad celíaca, de la sensibilidad al gluten no celíaca y de la enfermedad celíaca refractaria

Country Status (11)

Country Link
EP (1) EP3472202A1 (ru)
JP (2) JP2019521981A (ru)
CN (1) CN109311972A (ru)
AR (1) AR108790A1 (ru)
AU (1) AU2016411388A1 (ru)
BR (1) BR112018076287A2 (ru)
CA (1) CA3020894A1 (ru)
EA (1) EA201892707A1 (ru)
MX (1) MX2018015363A (ru)
TW (2) TW201803591A (ru)
WO (1) WO2017217985A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119246A1 (en) * 2016-12-21 2018-06-28 Cephalon, Inc. Antibodies that specifically bind to human il-15 and uses thereof
WO2020089396A2 (en) * 2018-10-31 2020-05-07 Tiziana Life Sciences Plc Composition and methods of treating inflammatory and autoimmune diseases
EP4384217A1 (en) 2021-08-12 2024-06-19 Amgen Inc. Antibody formulations
WO2024028448A1 (en) 2022-08-04 2024-02-08 Calypso Biotech Sa Il-15 inhibitors useful for the treatment of atopic dermatitis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247304B2 (en) * 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
JP4892335B2 (ja) * 2003-02-26 2012-03-07 ゲンマブ エー／エス インターロイキン１５（ｉｌ−１５）に特異的なヒト抗体
TW201031421A (en) * 2009-01-29 2010-09-01 Abbott Lab IL-1 binding proteins
WO2011031986A1 (en) * 2009-09-10 2011-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health Assays for soluble il-15 receptor alpha
EP2963057A1 (en) * 2014-07-02 2016-01-06 Calypso Biotech SA Antibodies to IL-15

Also Published As

Publication number Publication date
BR112018076287A2 (pt) 2019-03-26
WO2017217985A1 (en) 2017-12-21
TW202327653A (zh) 2023-07-16
CA3020894A1 (en) 2017-12-21
TW201803591A (zh) 2018-02-01
EP3472202A1 (en) 2019-04-24
EA201892707A1 (ru) 2019-05-31
MX2018015363A (es) 2019-04-15
JP2022001577A (ja) 2022-01-06
AU2016411388A1 (en) 2018-11-08
JP2019521981A (ja) 2019-08-08
CN109311972A (zh) 2019-02-05

Similar Documents

Publication Publication Date Title
AR105313A1 (es) Anticuerpo anti-cd137 terapéutico
PH12021550023A1 (en) Humanized anti-tau antibodies
AR099698A1 (es) Anticuerpos contra el c5 que tienen farmacocinética mejorada
AR104213A1 (es) Anticuerpos anti-cd38 como agentes terapéuticos
AR108790A1 (es) Métodos y composiciones para el tratamiento de la enfermedad celíaca, de la sensibilidad al gluten no celíaca y de la enfermedad celíaca refractaria
AR107290A1 (es) ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
AR103868A1 (es) Anticuerpos anti-cd47 como agentes terapéuticos
AR085281A1 (es) Moduladores de la proteina tirosina quinasa 7 (ptk7) y metodos para su uso
PE20191081A1 (es) Nuevos receptores de celulas t y terapia inmunologica que los utiliza
AR104280A1 (es) Terapia de combinación con factores de coagulación y anticuerpos multiespecíficos
AR104812A1 (es) Combinaciones terapéuticas y métodos para tratar neoplasias
AR083740A1 (es) Anticuerpos dkk1 (dickkopf-1) y metodos de uso
CY1109877T1 (el) Αντισωματα εναντι αμυλοειδους-βητα πεπτιδιου
CR20190468A (es) Métodos para tratar enfermedades y trastornos mediados por completo
MX2023002554A (es) Anticuerpos anti-il-1r3 humanizados.
PE20141683A1 (es) Anticuerpos monoclonales especificos para el antigeno m2-1 del virus respiratorio sincicial (vrs)
CO2021000914A2 (es) Productos y métodos de virus adenoasociado recombinante para el tratamiento de la distrofia muscular de cinturas 2a
AR095499A1 (es) ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b
MX2021011269A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina.
NZ750451A (en) Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6
BR112015012497A2 (pt) combinações farmacêuticas
EA201890623A1 (ru) Рациональная комбинированная терапия для лечения рака
AR104721A1 (es) Fragmento fab anti-ngf humano
MX2020004074A (es) Producto de combinacion para el tratamiento de cancer.
AR099907A1 (es) Composición farmacéutica usada en la prevención y/o el tratamiento de enfermedades causadas y/o agravadas por una disminución o deficiencia de la actividad del factor de coagulación sanguínea viii y/o del factor de coagulación sanguínea viii activado